Sugi Predict

Sugi Predict / Compounds / SCHEMBL185087

SCHEMBL185087

SCHEMBL185087

COC(=O)c1ccc(Cn2ccc([N+](=O)[O-])n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.53
▸ KMT2A Q03164 4/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ FAAH O00519 1/20 0.48
▸ GAA P10253 2/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ DCTPP1 Q9H773 1/20 0.46
▸ PKM P14618 2/20 0.44
▸ F2 P00734 1/20 0.44
▸ PLAU P00749 1/20 0.44
▸ KLKB1 P03952 1/20 0.44
▸ ELANE P08246 1/20 0.44
▸ POLB P06746 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ LOXL2 Q9Y4K0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29665356 0.88 LMNA (0.54) LMNAKMT2AMEN1GAARAB9A
SCHEMBL1865448 0.85 ABHD6 (0.52) LMNAKMT2AMEN1GAASMN1; SMN2
SCHEMBL3933302 0.84 CYP4A11 (0.50) LMNAKMT2AMEN1FAAHSMN1; SMN2
SCHEMBL10783151 0.83 LMNA (0.53) LMNAKMT2AMEN1GAAPKM
SCHEMBL17316285 0.82 LMNA (0.49) LMNAKMT2AMEN1GAARAB9A
SCHEMBL1167317 0.81 ALDH1A1 (0.59) LMNAKMT2AMEN1GAARAB9A
SCHEMBL1861673 0.81 KMT2A (0.49) LMNAKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL17316432 0.81 PKM (0.52) LMNAKMT2AMEN1GAAPKM
SCHEMBL15172489 0.80 RAB9A (0.60) LMNAKMT2AMEN1FAAHGAA
SCHEMBL1857009 0.79 LMNA (0.52) LMNAKMT2AMEN1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-03-06 — — US disclosed
EP-4452966-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
WO-2023115149-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 — — EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 — — US disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 — — US disclosed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 — — EP disclosed
US-7935699-B2 Pyrazole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2011-05-03 — — US disclosed
US-7902248-B2 C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus HOFFMANN-LA ROCHE INC. (US) 2011-03-08 — — US disclosed
EP-2261216-A2 Pyrazoles as glucokinase activators F. Hoffmann-La Roche AG (CH) 2010-12-15 — — EP disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 — — US disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 — — US disclosed
EP-2046755-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. Hoffmann-Roche AG (CH) 2009-04-15 — — EP disclosed
US-20080146625-A1 C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus BERTHEL STEVEN JOSEPH 2008-06-19 — — US disclosed
WO-2008012227-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-31 — — WO disclosed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP9 LMNA 1045/4885KMT2A 2755/4885MEN1 1140/4885
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA LMNA 2989/4885KMT2A 1928/4885MEN1 3139/4885
US-20080146625-A1 C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus GCK, PC, PCK2 LMNA 3474/4885KMT2A 967/4885MEN1 4194/4885
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 LMNA 4599/4885KMT2A 4296/4885MEN1 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.